Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial

References

• McCullers JA, Saito T, Iverson AR. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol. 2004;78:12817-28. doi:10.1128/JVI.78.23.12817-12828.2004. PMID:15542634
   PubMed Web of Science ®Google Scholar
• Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990;175:59-68. doi: not available. doi:10.1016/0042-6822(90)90186-U. PMID:2309452
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Past Weekly Surveillance Reports. Atlanta, Georgia: CDC;2016 [accessed 2016 Dec 28]. http://www.cdc.gov/flu/weekly/pastreports.htm.
   Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2014–2015. Ottawa, Canada: Public Health Agency of Canada;2014 [accessed 2016 Aug 29]. http://www.phac-aspc.gc.ca/naci-ccni/flu-grippe-eng.php.
   Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81-8. doi:10.4161/hv.8.1.17623. PMID:22252006
   PubMed Web of Science ®Google Scholar
• Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, Henriques CM, Njouom R, Fasce RA, Yu H, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses. 2015;9 Suppl 1:3-12. doi:10.1111/irv.12319. PMID:26256290
   PubMed Web of Science ®Google Scholar
• Barr IG, Vijaykrishna D, Sullivan SG. Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill. 2016;21. doi:10.2807/1560-7917.ES.2016.21.4.30118. PMID:26848118
   PubMedGoogle Scholar
• Zhao B, Qin S, Teng Z, Chen J, Yu X, Gao Y, Shen J, Cui X, Zeng M, Zhang X. Epidemiological study of influenza B in Shanghai during the 2009–2014 seasons: implications for influenza vaccination strategy. Clin Microbiol Infect. 2015;21:694-700. doi:10.1016/j.cmi.2015.03.009. PMID:25882368
   PubMed Web of Science ®Google Scholar
• Harvala H, Smith D, Salvatierra K, Gunson R, von Wissmann B, Reynolds A, Frew C, MacLean A, Hunt A, Yirrell D, et al. Burden of influenza B virus infections in Scotland in 2012/13 and epidemiological investigations between 2000 and 2012. Euro Surveill. 2014;19:1-7. doi:10.2807/1560-7917.ES2014.19.37.20903.
   Google Scholar
• Tran D, Vaudry W, Moore D, Bettinger JA, Halperin SA, Scheifele DW, Jadvji T, Lee L, Mersereau T. Hospitalization for Influenza A Versus B. Pediatrics. 2016;138. doi:10.1542/peds.2015-4643. PMID:27535144
   PubMed Web of Science ®Google Scholar
• Sharabi S, Drori Y, Micheli M, Friedman N, Orzitzer S, Bassal R, Glatman-Freedman A, Shohat T, Mendelson E, Hindiyeh M, et al. Epidemiological and Virological Characterization of Influenza B Virus Infections. PLoS One. 2016;11:e0161195. doi:10.1371/journal.pone.0161195. PMID:27533045
   PubMed Web of Science ®Google Scholar
• Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 2013;31:5572-8. doi:10.1016/j.vaccine.2013.08.069. PMID:24016810
   PubMed Web of Science ®Google Scholar
• Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 2015;33:2485-92. doi:10.1016/j.vaccine.2015.03.065. PMID:25843270
   PubMed Web of Science ®Google Scholar
• Pepin S, Szymanski H, Rochin Kobashi IA, Villagomez Martinez S, Gonzalez Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, et al. Safety and immunogenicity of an intramuscular quadrivalent Influenza vaccine in children 3 to 8 years of age: a phase III randomised controlled study. Hum Vaccin Immunother. 2016;12:0. doi:10.1080/21645515.2016.1212143.
   PubMed Web of Science ®Google Scholar
• Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34:4092-102. doi:10.1016/j.vaccine.2016.06.064. PMID:27381642
   PubMed Web of Science ®Google Scholar
• Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. J Infect Dis. 2015;212:1914-22. doi:10.1093/infdis/jiv313. PMID:26014800
   PubMed Web of Science ®Google Scholar
• Mutsaerts E, Madhi SA, Cutland CL, Jones S, Hugo A, Trenor S, Treurnicht FK, Klipstein-Grobusch K, Weinberg A, Nunes MC. Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Rev Vaccines. 2016;15:1055-62. doi:10.1080/14760584.2016.1192473. PMID:27212228
   PubMed Web of Science ®Google Scholar
• Houdouin V, Lavis N, Meyzer C, Jeziorski E, Merlin E, Pinquier D, Deschenes G, Mothe E, Petit C, Plantaz D, et al. Safety of the Northern Hemisphere 2014/2015 formulation of the inactivated split-virion intramuscular trivalent influenza vaccine. Vaccine Reports. 2016;6:1-7. doi: not available. doi:10.1016/j.vacrep.2016.07.001. PMID:28580433
   PubMedGoogle Scholar
• Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine. 2015;33:1151-9. doi:10.1016/j.vaccine.2015.01.025. PMID:25613721
   PubMed Web of Science ®Google Scholar
• Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines. 2010;9:1127-33. doi:10.1586/erv.10.117. PMID:20923264
   PubMed Web of Science ®Google Scholar
• Haq K, McElhaney JE. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38-42. doi:10.1016/j.coi.2014.03.008. PMID:24769424
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-40. doi:10.1001/jama.292.11.1333. PMID:15367555
   PubMed Web of Science ®Google Scholar
• McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev. 2011;10:379-88. doi:10.1016/j.arr.2010.10.008. PMID:21055484
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Control and Prevention. Influenza vaccination. 2005-2015. doi:https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/influenza-vaccination
   Google Scholar
• United States Food and Drug Administration. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Rockville, MD: US FDA, 2007.
   Google Scholar
• Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011;203:1309-15. doi:10.1093/infdis/jir015. PMID:21378375
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011;204:1879-85. doi:10.1093/infdis/jir661. PMID:21998477
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15:967-76. doi:10.1586/14760584.2016.1164046. PMID:26954563
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081-5. doi:10.1097/INF.0b013e3182367662. PMID:21983214
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Drinka P, Duthie EH, Miller BA, Brown CS, Hensley M, Circo R, Langer E, Ershler WB. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994;42:245-51. doi:10.1111/j.1532-5415.1994.tb01746.x. PMID:8120307
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Guideline on influenza vaccines. Non-clinical and clinical module London, UK: European Medicines Agency, 2016.
   Google Scholar
• Dunning AJ, DiazGranados CA, Voloshen T, Hu B, Landolfi VA, Talbot HK. Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016;23:228-35. doi:10.1128/CVI.00604-15. PMID:26762363
   PubMed Web of Science ®Google Scholar
• Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel). 2014;2:707-34. doi:10.3390/vaccines2040707. PMID:26344888
   PubMedGoogle Scholar
• US Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. Atlanta, Georgia: CDC;25 Aug 2016 [accessed 28 Dec 2016]. http://www.cdc.gov/flu/about/disease/high_risk.htm.
   Google Scholar
• World Health Organization. Serological diagnosis of influenza by microneutralization assay. 2010. http://www.who.int/influenza/gisrs_laboratory/2010_12_06_serologimicroneutralizationassay.2010.cal_diagnosis_of_influenza_by_microneutralization_assay.pdf
   Google Scholar